IBA and Apollo Hospitals sign a term sheet for one Proteus®ONE system plus a second one in option to be installed in India
04 March 2025 - 9:16PM
UK Regulatory
IBA and Apollo Hospitals sign a term sheet for one Proteus®ONE
system plus a second one in option to be installed in India
Louvain-La-Neuve, Belgium, March 04,
2025 – IBA (Ion Beam Applications S.A., EURONEXT), the
world leader in particle accelerator technology and leading
provider of proton therapy solutions for the treatment of cancer,
today announces it has signed a term sheet with Apollo Hospitals
Enterprise Limited (AHEL) for the supply of one
Proteus®ONE1 compact proton therapy solution
plus a second one in option. Apollo will therefore expand access to
proton therapy in India. The term sheet was signed in the presence
of Her Royal Highness Princess Astrid of Belgium.
These systems expand upon the existing
collaboration between the two partners, with AHEL having previously
selected an IBA Proteus®PLUS1 system in 2013
and introduced the first proton beam therapy in India. AHEL expects
to start treating patients with the Proteus®ONE systems
by 2028.
Proteus®ONE is the market leading
compact proton therapy system, which is upgradable over time to
continue providing the latest technology to IBA users. The systems
will include DynamicARC®2 beam delivery
capabilities when regulatory clearance is granted.
The typical end-user price for a
Proteus®ONE system with a multi-year maintenance
contract ranges between EUR 35 and 45 million.
Olivier Legrain, Chief Executive Officer of
IBA, commented: “These contracts expand upon the close
relationship we have built for more than a decade with Apollo
Hospitals. Having an existing customer reaffirm their confidence in
our solutions demonstrates not only the reliability and superiority
of the IBA portfolio but also highlights the level of excellence of
the services we deliver. We look forward to further strengthening
our relationship with Apollo as we enable more patients in India to
gain access to this life-saving treatment modality.”
Dr. Prathap C Reddy, Founder and Chairman of
Apollo Hospitals Enterprise Ltd, added: “Our relentless
pursuit of excellence in healthcare drives us to bring the most
advanced medical technologies to India. In 2019, Apollo
commissioned the first proton therapy system in India and till date
we have treated over 2000 patients from over 147 countries. We are
excited to partner with IBA again as we expand our proton therapy
treatment capacity. The addition of
Proteus®ONE further cements our position
as a global leader in proton beam therapy treatments, enabling us
to deliver superior clinical outcomes and improve the quality of
life for cancer patients in India and worldwide.”
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the fields of proton
therapy, considered to be the most advanced form of radiation
therapy available today, industrial sterilization,
radiopharmaceuticals, and dosimetry. The company, based in
Louvain-la-Neuve, Belgium, employs approximately 2,000 people
worldwide. IBA is a certified B Corporation (B Corp) meeting the
highest standards of verified social and environmental
performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More
information can be found at: www.iba-worldwide.com
About Apollo Hospitals Entreprise
Limited
Apollo Hospitals Enterprise Ltd (AHEL) revolutionised healthcare
when Dr. Prathap C. Reddy opened the first hospital in Chennai in
1983. Today, AHEL is India’s largest integrated healthcare platform
with over 10,000 beds across 73 hospitals, over 6000 pharmacies and
over 200 clinics and diagnostic centres, as well as 150
telemedicine centres. It is the world’s leading Cardiac Centre with
over 200,000 surgeries and the world’s largest private cancer care
provider. Apollo continues to invest in research to bring the most
cutting-edge technologies, equipment and treatment protocols to
ensure patients have the best available care in the world. Apollo’s
100,000 family members are dedicated to bringing the best care
making a better world.
CONTACTS
IBA
Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com
ICR Healthcare
Amber Fennell, Angela Gray, Lucy Featherstone
+44 (0) 20 3709 5700
IBA@icrhealthcare.com
1 Proteus®ONE and Proteus®PLUS
are the brand names of Proteus®235.
2 DynamicARC® is a registered brand of the IBA’s
Proton Arc therapy solution currently under development phase.
- 250305_IBA-Apollo-2ProteusONE_term-sheet-EN-final
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
From Feb 2025 to Mar 2025
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
From Mar 2024 to Mar 2025
